NeOnc Technologies Holdings, Inc. (NTHI)
NASDAQ: NTHI · Real-Time Price · USD
9.84
+1.36 (16.04%)
Sep 10, 2025, 2:53 PM - Market open
NTHI Revenue
NeOnc Technologies Holdings had revenue of $59.99K in the twelve months ending June 30, 2025, down -4.78% year-over-year. In the year 2024, NeOnc Technologies Holdings had annual revenue of $83.00K with 17.79% growth.
Revenue (ttm)
$59.99K
Revenue Growth
-4.78%
P/S Ratio
2,702.52
Revenue / Employee
$7,499
Employees
8
Market Cap
188.53M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 83.00K | 12.54K | 17.79% |
Dec 31, 2023 | 70.46K | 50.46K | 252.31% |
Dec 31, 2022 | 20.00K | - | - |
Dec 31, 2021 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionNTHI News
- 16 days ago - NeOnc Technologies Closes Strategic Acquisition of Advanced AI and 3D Bioprinting IP, Appointing World-Renowned Scientist Dr. Ishwar K. Puri to its Board - GlobeNewsWire
- 4 weeks ago - NeOnc Technologies Finalizes All Contingencies for $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation - GlobeNewsWire
- 4 weeks ago - NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia - GlobeNewsWire
- 5 weeks ago - NeOnc Technologies Featured on Yahoo Finance's Podcast Trader Talk: AI and Biotech Take on Brain Cancer - GlobeNewsWire
- 6 weeks ago - NeOnc Technologies Signs Definitive Agreement to Acquire AI, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri; Appoints Him to Board of Directors - GlobeNewsWire
- 7 weeks ago - CORRECTING and REPLACING - NeOnc Technologies Holdings, Inc. - GlobeNewsWire
- 2 months ago - NeOnc Technologies Signs $50 Million Non-Binding Strategic Term Sheet with Quazar Investment to Launch GCC & MENA Expansion and Clinical Trials Platform - GlobeNewsWire
- 3 months ago - NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs - GlobeNewsWire